Cyclacel Pharmaceuticals, Inc. Profile Avatar - Palmy Investing

Cyclacel Pharmaceuticals, Inc.

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK…

Biotechnology
US, Berkeley Heights [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Cyclacel Pharmaceuticals, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of CYCC's Analysis
CIK: 1130166 CUSIP: 23254L603 ISIN: US23254L8019 LEI: - UEI: -
Secondary Listings
CYCC has no secondary listings inside our databases.